Skip to NavigationSkip to content


Sanofi accuses MSD of US patent infringement

Sanofi has filed a suit against MSD in the United States District Court for the District of Delaware accusing the US firm of infringing ten of its patents.

This move comes after a notification that MSD has filed a New Drug Application with the FDA for an insulin glargine drug product; the company asserts that its NDA included a paragraph IV certification challenging all of the ten patents listed in the FDA Orange Book for Sanofi’s Lantus and Lantus SoloStar products.

Matt Fellows

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the US and Canada, for Keytruda (pembrolizumab) as a first-line treatment for patients with advanced non-small cell lung cancer.

MSD drops osteoporosis trial drug due to stroke risk

MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development of osteoporosis drug, odanacatib, and will not seek regulatory approval for its use.

The investigational cathepsin K inhibitor has hit numerous stumbling blocks throughout the trial process, with the drug failing to make it past regulators as far back as 2013 due to its adverse events profile.

MSD joins Medivation race, says reports

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology drugs firm Medivation, according to a report by Reuters.

MSD to cut 148 jobs at Pennsylvania plant

MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s Worker Adjustment and Retraining Notification filed with the State Department.

Spokeswoman Lainie Keller remarked that the decision is a result of the company’s move to cease production of its heart drug Zontivity after September 2, meaning that field-based team members and other HQ-based roles will be displaced.  

FDA approves MSD’s Keytruda for head and neck cancer treatment

The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy.

MSD files Lantus biosimilar with FDA

MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and Drug Administration (FDA) for MK-1293, a biosimilar candidate for Sanofi’s Lantus (insulin glargine) in the treatment of type-1 and type-2 diabetes.

Takeover rumours send Biogen’s stock soaring

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a Wall Street Journal cited people familiar with the matter.

Any deal for Biogen would easily be one of the largest in the industry’s history. After the initial talk emerged over a potential takeover bid, Biogen stock rose almost 10% to $330 per share, with a market cap of $75.3 billion.

MSD scores EU approval for Keytruda in lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients with locally advanced or metastatic non-small cell lung cancer in patients whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen.

400 current and former employees join sexual discrimination lawsuit against MSD

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in the US and Canada, according to counsel for the plaintiffs, Sanford Heisler LLP.

According to the women involved, who include both current and former employees, MSD paid female sales representatives less than their male counterparts and prevented women from climbing the corporate ladder. The claim was originally filed by just one plaintiff, former employee Kelli Smith, in 2013.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches